Experience of using lumacaftor/ivacaftor in children with cystic fibrosis in the Astrakhan region
https://doi.org/10.29413/ABS.2022-7.4.12
Abstract
Background. Targeted therapy in patients with cystic fibrosis, which aims to restore the function of the cystic fibrosis transmembrane conductance regulator protein, is currently revolutionary in the treatment of the disease. The first drug available in Russia for the treatment of patients with this genetic disease is lumacaftor/ivacaftor (Orkambi®), which was registered on December 2, 2020.
The aim. To study the efficacy of lumacaftor/ivacaftor during 12 weeks of administration in children in Astrakhan region.
Materials and methods. This article presents the clinical experience of Orkambi medicine use in 3 children with F508del/F508del genotype and a severe course of cystic fibrosis for 12 weeks. According to the study design, such indices as body mass index, indexes of external respiratory function, character of respiratory tract microbiota, level of chloride in sweat fluid and pancreatic elastase in feces, dynamics of biochemical blood indexes were evaluated. The study was performed within the time periods specified in the study protocol, namely, before the start of therapy, 2, 4, and 12 weeks of treatment.
Results. Two patients had a decrease in sweat test values by 11 and 19 mmol/l from the baseline, a significant increase in forced vital capacity of lungs. One patient had an adverse event in the form of hepatobiliary disorders manifested by increased liver transaminase activity, which was the reason for discontinuing the drug.
Conclusions. The short-term experience of using pathogenetic therapy with lumacaftor/ ivacaftor in children in the Astrakhan region demonstrated both the expected effect on chlorine channel function and the possibility of side effects, including severe ones, that can lead to withdrawal of the drug.
About the Authors
A. R. Kosareva
Astrakhan State Medical University
Russian Federation
Russian Federation
Anastasia R. Kosareva – Student at the Medical Faculty
Bakinskaya str. 121, Astrakhan 414000
O. A. Bashkina
Astrakhan State Medical University
Russian Federation
Russian Federation
Olga A. Bashkina – Dr. Sc. (Med.), Professor, Rector, Head of the Department of Faculty Pediatrics
Bakinskaya str. 121, Astrakhan 414000
D. F. Sergienko
Astrakhan State Medical University
Russian Federation
Russian Federation
Diana F. Sergienko – Dr. Sc. (Med.), Professor at the Department of Faculty Pediatrics
Bakinskaya str. 121, Astrakhan 414000
References
1. Kapranov NI, Kashirskaya NYu, Cystic fibrosis. Moscow: Medpraktika-M; 2014. (In Russ.).
2. Clinical and functional translation of CFTR. URL: https://www.CFTR2.org [date of access: 01.02.2022].
3. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016; 4(8): 662-674. doi: 10.1016/S22132600(16)00023-0
4. Derichs N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fi osis. Eur Respir Rev. 2013; 22(127): 58-65. doi: 10.1183/09059180.00008412
5. Middleton PG, Mall МА, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019; 381(19): 18091819. doi: 10.1056/NEJMoa1908639
6. Amelina EL, Krasovskiy SA, Usacheva MV, Krylova NA. Pathogenic treatment of cystic fibrosis: the first clinical case in Russia. Pulmonologiya. 2017; 27(2): 298-301 (In Russ.). doi: 10.18093/08690189-2017-27-2-298-301
7. Amelina EL, Krasovskiy SA, Shumkova GL, Krylova NA. Targeted therapy for CF patients with F508del/F508del genotype. Pulmonologiya. 2019; 29(2): 235-238. (In Russ.). doi: 10.18093/08690189-2019-29-2-235-238
8. Kondratyeva EI, Amelina EL, Chernukha MYu, Sherman VD, Krasovskiy SA, Kashirskaya NYu, et al. Review of clinical guidelines “Cystic fibrosis”, 2020. Pulmonologiya. 2021; 31(2): 135-146. (In Russ.). doi: 10.18093/0869-0189-2021-31-2-135-146
9. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3): 220-231. doi: 10.1056/NEJMoa1409547
10. McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, et al. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: An open-label phase 3 study. Lancet Respir Med. 2019; 7(4): 325-335. doi: 10.1016/S2213-2600(18)30460-0
11. Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: Design, development and place in therapy. Drug Des Devel Ther. 2019; 13: 2405-2412. doi: 10.2147/DDDT.S153719
12. Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, et al. Assessment of safety and effi y of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): A phase 3, extension study. Lancet Respir Med. 2017; 5(2): 107-118. doi: 10.1016/S2213-2600(16)30427-1
13. Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, et al. VX14-809-109 investigator group. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: A randomised, placebo controlled phase 3 trial. Lancet Respir Med. 2017; 5(7): 557-567. doi: 10.1016/S2213-2600(17)30215-1
14. Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, et al. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: A phase 3, open-label, extension study. Lancet Respir Med. 2021; 9(7): 721-732. doi: 10.1016/S22132600(20)30517-8
15. Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, et al. Long-term safety of lumacaftor-ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508delCFTR mutation: A multicentre, phase 3, open-label, extension study. Lancet Respir Med. 2021; 9(9): 977-988. doi: 10.1016/S22132600(21)00069-2
16. Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, et al. Effects of lumacaftor ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in Phe508del homozygous patients with cystic fibrosis. Am J Respir Crit Care Med. 2018; 197(11): 1433-1442. doi: 10.1164/rccm.201710-1983OC
Review
For citations:
Kosareva A.R., Bashkina O.A., Sergienko D.F. Experience of using lumacaftor/ivacaftor in children with cystic fibrosis in the Astrakhan region. Acta Biomedica Scientifica. 2022;7(4):101-108. (In Russ.) https://doi.org/10.29413/ABS.2022-7.4.12
Views:
961
.png)
Email this article 
